Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

9,0834,977,450General and administrative

1,001,5381,019,7472,062,5542,129,129Total operating expenses

3,447,3083,712,8146,851,6377,106,579Loss from operations

(3,440,753)(3,701,322)(6,841,276)(7,067,870)OTHER INCOME (EXPENSE):Investment income

13,0167,23427,38722,274Interest expense

(1,360)(1,847)(3,642)(4,820)Increase in fair value of warrants

--(7,069,165)-Gain on disposition of supplies

 and equipment

-3,0004,6203,000Total other income (expense), net

11,6568,387(7,040,800)20,454Loss before income taxes

(3,429,097)(3,692,935)(13,882,076)(7,047,416)Income tax benefit

1,753,2081,068,2331,753,2081,068,233NET LOSS

$
(1,675,889)$
(2,624,702)$
(12,128,868)$
(5,979,183)Basic and diluted net loss per

 common share

$
(0.02)$
(0.08)$
(0.14)$
(0.17)Weighted average number of

 common shares outstanding used

 in computing basic and diluted

 net loss per common share

106,424,44334,900,59189,046,80634,900,591 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets(unaudited)December 31, 2012June 30, 2012ASSETSCurrent assets:Cash and cash equivalents

$
32,850,676$
3,827,198Accounts receivable

37,99127,631Restricted cash

-350,000Prepaid expenses and other current assets

343,912532,010Total current assets

33,232,5794,736,839Property and equipment, net

285,649318,653Other assets

58,542324,992Total assets

$
33,576,770$
5,380,484LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

$
23,144$
22,277Accounts payable 

484,815294,894Accrued expenses

1,541,7292,706,496Accrued compensation

-433,333Total current liabilities

2,049,6883,457,000Capital lease obligations 

8,11619,909Deferred rent'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... 18 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), ... Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome, ... Healthcare Products Regulatory Agency (MHRA). BioMarin expects to initiate ...
... Inc. (OTC Bulletin Board: CSBR), a company engaged in ... data to enhance the value of oncology drugs, reports ... January 31, 2009. Full details of the Company,s ... at www.championsbiotechnology.com . Total revenues for the third ...
... forces), used by ergonomic engineers worldwide, is now more versatile and ... capacities have been doubled to accurately measure up to 300 lbs. ... ... 2009 -- HOGGAN Ergo, Ergonomic Division of HOGGAN Health Industries, ...
Cached Biology Technology:BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 6HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 2HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 3
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
... Like their human hosts, bacteria need iron to survive and ... obtain iron primarily through the food they eat, bacteria have ... iron. A Syracuse University research team led by Robert ... and Sciences, discovered that some bacteria are equipped with a ...
... to achieve normal levels of blood sugar in ... levels. If this approach succeeds in humans, it ... congenital hyperinsulinism, a rare but potentially devastating genetic ... "There is currently no effective medical treatment ...
... the lowliest bacterium use molecules to communicate. Some chemicals ... still others are used to attract members of the ... have now found a rare kind of signaling molecule ... serves a dual purpose, working as both a population-control ...
Cached Biology News:Syracuse University scientists discover how some bacteria may steal iron from their human hosts 2Syracuse University scientists discover how some bacteria may steal iron from their human hosts 3Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 2Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 3
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: